Panbela therapeutics announces exercise of warrants and issuance of new warrants in a private placement for $1.9 million gross proceeds priced at-the-market

Minneapolis, nov. 03, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,130,000 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.78 per share, in exchange for new warrants as described below. the aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1.9 million, before deducting financial advisory fees. the reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under nasdaq rules.
PBLA Ratings Summary
PBLA Quant Ranking